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REVIEW
Abstract: Survivors of myocardial infarction (MI) are at high risk of disability and death.
This is due to infarct-related complications such as heart failure, cardiac remodeling with
progressive ventricular dilation, dysfunction, and hypertrophy, and arrhythmias including
ventricular and atrial fibrillation. Angiotensin (Ang) II, the major effector molecule of the
renin–angiotensin–aldosterone system (RAAS) is a major contributor to these complications.
RAAS inhibition, with angiotensin-converting enzyme (ACE) inhibitors were first shown to
reduce mortality and morbidity after MI. Subsequently, angiotensin receptor blockers (ARBs),
that produce more complete blockade of the effects of Ang II at the Ang II type 1 (AT1)
receptor, were introduced and the ARB valsartan was shown to be as effective as an ACE
inhibitor in reducing mortality and morbidity in high-risk post-MI suvivors with left ventricular
(LV) systolic dysfunction and and/or heart failure and in heart failure patients, respectively,
in two major trials (VALIANT and Val-HeFT). Both these trials used an ACE inhibitor as
comparator on top of background therapy. Evidence favoring the use of valsartan for secondary
prevention in post-MI survivors is reviewed.
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Introduction
This article reviews the rationale and evidence for inhibition of the renin–angiotensin–
aldosterone system (RAAS) by the angiotensin (Ang) II type 1 (AT1) receptor blocker
(ARB) valsartan in survivors of myocardial infarction (MI) with left ventricular (LV)
systolic dysfunction and/or heart failure, either on top of background therapy including
angiotensin-converting enzyme (ACE) inhibitors or instead of ACE inhibitors in
patients who are intolerant to them. The results of Valsartan in Acute MI trial
(VALIANT) in high-risk survivors of MI and Valsartan Heart Failure Trial (Val-
HeFT) in heart failure patients and their substudies, and the evidence favoring the
use of valsartan for secondary prevention in survivors of MI are also reviewed.
RAAS inhibition: ACE inhibitors and ARBs
The role of the RAAS in cardiovascular (CV) disease was first recognized nearly
five decades ago. The initial focus was on hypertension and the neurohumoral
paradigm. Over the last two decades, ACE inhibitors have become established for
the treatment of hypertension, heart failure, and MI as a result of several large-scale,
multicenter randomized clinical trials (RCTs). The rationale for using ACE inhibitors
was to inhibit ACE (Figure 1) and thereby decrease the formation of Ang II, the
primary effector molecule of the RAAS that was linked to the pathophysiology of
CV disease (Figure 2). Several major ACE inhibitor trials (Table 1) have established
its use for improving the survival of patients with heart failure and acute MI. This
was a major advance in CV medicine during the latter half of the 20th century.
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Over the last one and a half decades, several RCTs have
investigated the benefits of using ARBs in patients with heart
failure and MI (Table 2). The rationale for using ARBs was
to achieve specific and selective blockade of the effects of
Ang II via the AT1 receptor (Timmermans et al 1991).
Several other reasons were later proposed as justification
for using ARBs on top of or instead of the already established
ACE inhibitors. First, compared with ACE inhibitors, ARBs
might provide more complete inhibition of Ang II derived
from all sources, including non-ACE and non-renin
pathways, especially as the latter is increased during ACE
inhibition (Urata et al 1990; de Gasparo and Levens
1998). However, ARBs were later found to increase renin,
Ang I and Ang II levels as well as Ang 1-7 levels
(Ferrario, Jessup, et al 2005; Ferrario, Trask, et al 2005).
Second, ARBs do not inhibit kininase II or increase, via
this mechanism, systemic peptides of the inflammatory
response such as bradykinin, substance P, and other
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Figure 1 Angiotensin II formation and degradation pathways. Updated from Jugdutt BI. 1998. Angiotensin receptor blockers. In: Crawford MH (ed). Cardiology Clinics
Annual of Drug Therapy. Philadelphia: WB Saunders Pub, Vol 2, pp 1–17. Copyright © 1998. Reprinted with permission from Elsevier, with data from Ferrario CM, Trask
AJ, Jessup JA. 2005. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am
J Physiol, 289:H2281-90. Copyright © 2005.
Abbreviations: ACE, angiotensin-converting enzyme; CAGE, chymostatin-sensitive angiotensin II generating enzyme; t-PA, tissue plasminogen activator.
Table 1 Major trials of ACE inhibitors in heart failure and myocardial infarction
Year,  Trial, Reference N Disease Drug Outcome
1987 The CONSENSUS Trial Study Group  253 HF Enalapril 27% ↓ mortality; ↓morbidity
1991 The SOLVD Investigators (symptomatic)  2569 HF Enalapril 16% ↓ mortality; ↓ morbidity
1992 The SOLVD Investigators (asymptomatic)  4228 HF Enalapril 8% ↓ mortality (NS); ↓ morbidity
1992 CONSENSUS II, Swedberg et al  6090 MI Enalapril No decrease in mortality; hypotension
1992 The SAVE Trial, Pfeffer et al  512 MI Captopril 19% ↓ mortality; ↓ morbidity
1993 The AIRE Study Investigators  2006 MI Ramipril 27% ↓ mortality; ↓ morbidity
1994 GISSI-3 Trial (6-week effects) 19 394 MI Lisinopril 11% ↓ mortality; ↓ morbidity
1995 ISIS-4 Trial 58 050 MI Captopril 7% ↓ mortality; ↓ morbidity
1995 TRACE Study, Kober et al.  6676 MI Trandolapril 34.7% ↓ mortality; ↓ morbidity
1995 CCS-1, Lisheng et al 13 634 MI Captopril 6% ↓ mortality; ↓ morbidity
1995 SMILE, Ambrosioni et al  1556 MI Zofenopril 29% ↓ mortality; ↓ morbidity
1996 The GISSI-3 Trial (6-month effects) 19 394 MI Lisinopril 6.2% ↓ (mortality + LV dysfunction) combined
1997 HEART, Pfeffer et al  352 MI Ramipril ↓ LV remodeling
Abbreviations: ↓, decrease in; ACE, angiotensin-converting enzyme; AIRE, Acute Infarction Ramipril Efficacy; CCS, Chinese Captopril Study; CONSENSUS,
Cooperative New Scandinavian Enalapril Survival Study; GISSI, Gruppo Italiano per lo Studio della Sopravivvenza nell’ Infarcto Miocardio; HEART, Healing and Early
Afterload Reducing Therapy; HF, heart failure; ISIS-3, Fourth International Study of Infarct Survival; LV, left ventricular; MI, myocardial infarction; N, number of patients;
NS, non-significant; SAVE, Survival and Ventricular Enlargement Trial; SMILE, Survival of Myocardial Infarction Long Term Evaluation; SOLVD, Studies of Left Ventricular
Dysfunction; TRACE, Trandolapril Cardiac Evaluation.Vascular Health and Risk Management 2006:2(2) 127
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tachykinins known to produce cough and angioedema:
side effects associated with ACE inhibitors (Benz et al
1997; Howes and Tran 2002). Third, ARBs might produce
unopposed stimulation of the Ang II type 2 (AT2) receptor
resulting in added benefits (Figure 3), including long-
term CV structural changes over that seen with ACE
inhibitors (de Gasparo and Levens 1998). The discovery
of ARBs may therefore be considered as another major
breakthrough in CV medicine towards the end of the 20th
century.
However, since the benefits of ACE inhibitors in
hypertension, heart failure, and MI were already established
when ARBs were introduced, it became necessary to
demonstrate that ARBs were superior to ACE inhibitors or
equally effective in patients intolerant to them and receiving
other background therapies in RCTs, rather than relative to
a true placebo group. Two RCTs have studied the effects of
valsartan in post-MI LV systolic dysfunction and/or heart
failure (Pfeffer, McMurray, et al 2003) and chronic heart
failure (Cohn et al 2001), respectively.
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Figure 2 Major cardiovascular effects of angiotensin II. Updated from Jugdutt BI. 1998. Angiotensin receptor blockers. In: Crawford MH (ed). Cardiology Clinics
Annual of Drug Therapy. Philadelphia: WB Saunders Pub, Vol 2, pp 1–17. Copyright © 1998. Reprinted with permission from Elsevier.
Abbreviations: AT1, angiotensin II type 1; AT2, angiotensin II type 2; B1, bradykinin 1; B2, bradykinin 2; NADPH, nicotinamide adenine dinucleotide phosphate, reduced.
Table 2 Major trials of ARBs in heart failure and myocardial infarction
 Year, Trial, Reference  N Disease ARB Comparator Outcome
1997 ELITE, Pitt et al   722 HF Losartan captopril Unexpected 46% ↑ in mortality (2° end-point)
1999 RESOLVD, McKelvie et al   768 HF Candesartan enalapril Early trend in ↑ mortality and HF (2° end-point)
2000 ELITE II, Pitt et al   3152 HF Losartan captopril Not superior
2001 Val-HeFT, Cohn et al   5010 HF Valsartan ACE-Is Not superior; ↓ composite end-point
2002 OPTIMAAL, Dickstein et al    5477 MI Losartan captopril Not superior (non-inferiority criteria not met)
2003b CHARM-Overall, Pfeffer et al   7601 HF Candesartan ACE-Is Improved 1° outcome (mortality and morbidity)
2003 CHARM-Added, McMurray et al   2548 HF Candesartan ACE-Is Improved 1° outcome (clinical, morbidity)
2003 CHARM-Alternative, Granger et al   2028 HF Candesartan ACE-Is Improved 1° outcome  (mortality and morbidity)
2003 CHARM-Preserved, Yusuf et al   3023 HF Candesartan ACE-Is Similar 1° outcome (improved 2° outcome)
2003a VALIANT, Pfeffer et al 14  703 MI Valsartan captopril Not superior, non-inferior
Abbreviations: ↑, increase in; ↓, decrease in; ACE, angiotensin-converting enzyme; ACE-Is, ACE inhibitors; ARB, angiotensin II type 1 receptor blocker; CHARM,
Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity; ELITE, Evaluation of Losartan in the Elderly; HF, heart failure; MI, myocardial
infarction; N, number of patients; RESOLVD, Randomized Evaluation of Strategies for Left Ventricular Dysfunction; Val-HeFT, Valsartan Heart Failure Trial; VALIANT,
Valsartan in Acute Myocardial Infarction; 1°, primary; 2°, secondary.Vascular Health and Risk Management 2006:2(2) 128
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Pharmacology of the RAAS
The pertinent aspects of RAAS inhibition have been
reviewed (Jugdutt 1998). Ang II has several important
physiological actions, including vasoconstriction,
aldosterone and catecholamine release, drinking, secretion
of prolactin and adrenocorticotrophic hormone, and
glycogenolysis (Jugdutt 1998). Ang II is also a pleiotropic
cytokine that plays a critical role in the pathophysiology of
several CV diseases. Thus, Ang II induces vasoconstriction
and stimulates growth, contributes to LV dysfunction and
progression of heart failure, mediates adverse structural
cardiac and vascular remodeling (Dzau 1993), and causes
deleterious activation of other neurohumoral agonists such
as norepinephrine, aldosterone, and endothelin (Figure 2).
Collective evidence indicates that Ang II is produced in
the circulation and tissues and acts on the AT1 and AT2
receptors (Jugdutt 1998; Dzau 2001), but most of the effects
of Ang II are mediated through the AT1 receptor. However,
in CV diseases such as myocardial hypertrophy, vascular
injury, MI, heart failure, and wound healing, the AT2 receptor
is upregulated and may mediate some CV effects of Ang II.
For example, in heart failure, there is a decrease in AT1 and
an increase in AT2 receptors. It has been proposed that the
antiproliferative and vasodilatory effects of AT2 balance the
growth-stimulating and vasoconstricting effects of AT1
receptors. In that concept, an ARB would completely block
effects of Ang II via AT1 and result in unopposed AT2
receptor stimulation that might augment its beneficial effects
(de Gasparo and Levens 1998). However, the role of AT2 in
humans remains controversial (Opie and Sack 2001).
Collective evidence also suggests that the CV protective
effects of ACE inhibitors are related not only to inhibition
of Ang II formation via ACE, but also to inhibition of the
breakdown of bradykinin and other tachykinins due to
ACE’s kininase II activity (Figure 3). Thus during ACE
inhibition, Ang II presented to both AT1 and AT2 receptors
is decreased, at least initially, so that decreased but balanced
AT1 and AT2 effects would be expected. However, increased
bradykinin stimulates nitric oxide (NO), prostaglandins such
as prostacyclin (PGI2,), endothelial-derived hyperpolarizing
factor (EDHF) and tissue-thromboplastin activator (t-PA),
thereby contributing to the vasodilation, CV protection and
other favorable vascular effects associated with ACE
inhibitors (Drexler 1994). Of note, increased bradykinin may
contribute to hypotensive effect of ACE inhibitors.
In contrast, the CV protective effect of ARBs is mediated
largely by AT1 blockade and partly via AT2 receptor
activation and via release of kinins and stimulation of kinin
B1 or B2 receptors (Seyedi et al 1995; Liu et al 1997) and/or
direct AT2 mediated signaling via protein kinase C (PKCε),
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Figure 3 Pathways of ACE-inhibitor and ARB-induced cardiovascular protection. Updated from Jugdutt BI. 1998. Angiotensin receptor blockers. In: Crawford MH (ed).
Cardiology Clinics Annual of Drug Therapy. Philadelphia: WB Saunders Pub, Vol 2, pp 1–17. Copyright © 1998. Reprinted with permission from Elsevier.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II type 1 receptor blocker; cGMP, cyclic guanosine 3′ 5′ monophosphate; EDHF, endothelium-
derived hyperpolarizing factor; eNOS, endothelial nitric oxide synthase; NADPH, nicotinamide adenine dinucleotide phosphate, reduced; NO, nitric oxide; PAI-1,
plasminogen activator inhibitor-1; PGI2, prostacyclin; PKCε, protein kinase Cε; t-PA, tissue plasminogen activator.Vascular Health and Risk Management 2006:2(2) 129
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nitric oxide (NO), and cyclic guanosine monophosphate
(cGMP) (Jugdutt et al 2000; Xu et al 2000; Jugdutt and
Balghith 2001) (Figure 3).
The discovery that ACE inhibitors do not block the
formation of all Ang II, such as that from Ang I via chymase
and other non-ACE enzymes, and/or that from
angiotensinogen via non-renin pathways, and Ang II levels
persist during long-term ACE inhibitor therapy (Kawamura
et al 1992; Jorde et al 2000), fueled the concept that the
combination of ACE inhibition and AT1 receptor blockade
may produce more complete blockade of the deleterious
effects of Ang II and produce greater benefits. Support for
this concept came from experimental (Spinale et al 1997)
and clinical (Hamroff et al 1999) studies in heart failure. In
the rat model of post-MI heart failure, valsartan combined
with the ACE inhibitor fosinopril suppressed histopathologic
changes associated with remodeling, and normalized
collagen I, macrophages and myofibroblasts (Yu et al 2001).
Extending that concept, valsartan combined with the
endothelin blocker bosentan was shown to produce additive
beneficial effects on loading, neurohumoral activity, and
LV performance in the atrial pacing-induced heart failure
in pigs (New et al 2000).
Recent advances have modified some traditional
concepts about the RAAS (Figure 1). Several studies have
underscored the importance of Ang II degradation by ACE2,
a regulator of cardiac function, to Ang-(1-7), a vasodilator,
antitrophic and antifibrotic heptapeptide that functions as
an endogenous inhibitor of Ang II (Ferrario, Trask, et al
2005; Iwata et al 2005). Both ACE2 and Ang-(1-7) have
been demonstrated in rat and human cardiomyocytes.
Experimentally in rats, ACE inhibition was shown to
decrease Ang II formation and increase Ang-(1-7), and AT1
blockade to increase Ang II and Ang-(1-7) (Ferrario, Jessup,
et al 2005). The increase in Ang-(1-7) with ACE inhibition
was attributed to increased Ang I and inhibition of Ang-(1-
7) metabolism, and that with AT1 blockade to formation from
increased Ang I. After MI in rats, AT1 blockade was shown
to upregulate ACE2 (Ishiyama et al 2004), which may
contribute to its cardioprotective effect via Ang-(1-7)
formation, as verified by Ang-(1-7) infusion (Loot et al
2002). As Ang-(1-7) is a substrate for inactivation by ACE,
it competes with Ang I and bradykinin for degradation,
thereby inhibiting Ang II formation and augmenting
bradykinin activity and its vasodilatory effects (Tom et al
2001). Increased Ang-(1-7) with ACE inhibition may further
augment bradykinin activity. Recently, AT1 blockade was
shown to increase bradykinin levels in hypertensive humans,
probably due to decreased metabolism by ACE and neutral
endopeptidase (Campbell et al 2005). The authors suggested
that the increased bradykinin with ARBs may augment
therapeutic actions, but also lead to angioedema.
Collectively, the findings indicate that both ACE inhibitors
and ARBs increase Ang-(1-7) and bradykinin.
It should be noted that ACE inhibitors and ARBs are
used on top of background therapy which often includes
beta-blockers, especially in patients with LV systolic
dysfunction and heart failure. Since beta-blockers also
reduce renin (Buhler et al 1972) and Ang II (Campbell et al
2001), they produce effects that are additive to those of ACE
inhibitors (Sharpe 1999).
Pharmacology of valsartan
The pharmacology of valsartan has been reviewed
(Criscione et al 1993; Markham and Goa 1997; Chiolero
and Bernier 1998; Chung et al 1999; Wellington and Faulds
2002). The chemical structure has similarities and
differences compared with other ARBs such as losartan,
candesartan, and irbesartan (Figure 4). Valsartan displays
non-competitive antagonism at the AT1 receptor (Chung et
al 1999). It also demonstrates partial insurmountable
antagonism in vitro, as do some other ARBs including
irbesartan and EXP3174. This feature of valsartan
antagonism may reflect slow dissociation from the AT1
receptor (half-life = 17 minutes) and may explain its
prolonged blood pressure (BP) lowering effect in clinical
studies (Verheijen et al 2000). Valsartan is quickly absorbed
after oral dosing, reaching peak plasma concentration in 2
hours, and has 20% bioavailability. Binding to protein,
mainly albumin, is 94% to 97%. Valsartan is mainly
eliminated unchanged in bile and <10% in urine. The
elimination half-life is 5–7 hours in patients. Metabolism
appears to be independent of the cytochrome P450 isoenzyme
system and 20% of the dose is recovered as metabolites.
Accumulation after daily dosage is minimal. The kinetics is
not affected by renal dysfunction. However, the dosage has
to be reduced in patients with liver dysfunction.
In heart failure it is advisable to start at a dose of 40 mg
twice daily (BID) and titrate to 160 mg BID. In heart failure
patients, valsartan produces significant decreases in
pulmonary capillary wedge pressure (p = 0.013), systolic BP
(p = 0.003), and plasma norepinephrine (p = 0.013) by 28
days (Baruch et al 1999). In LV dysfunction and/or heart
failure post MI (Pfeffer, McMurray, et al 2003), valsartan
was begun at 20 mg and escalated in steps to 40 mg, 80 mg,Vascular Health and Risk Management 2006:2(2) 130
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and 160 mg BID depending on the dose of captopril (target
50 mg three times daily [TID]).
Double jeopardy of MI survivors
and secondary prevention after MI
Survivors of MI represent a special group of patients at
double jeopardy for increased CV events, morbidity, and
mortality (Figure 5). First, they are at high risk for infarct-
related complications (such as progressive cardiac and
vascular remodeling, LV dysfunction and heart failure,
arrhythmias, and death). Second, they are exposed to risk
factors that antedated the MI and contribute to
atherosclerosis progression, myocardial ischemia, recurrent
MI, restenosis after revascularization/reperfusion
procedures, metabolic syndrome and type II diabetes
mellitus, peripheral vascular disease (PVD), arrhythmogenic
syndromes, ventricular dyssynchrony, stroke and other
cerebrovascular disease (CVD), and renal complications.
Importantly, MI survivors are increasing as a result of
improved therapies that have reduced mortality.
Comprehensive secondary prevention is therefore an
important aspect of therapy in the MI survivors.
Prevention of LV remodeling after
MI and RAAS inhibition
The pathophysiology and prevention of LV structural
remodeling after MI has been extensively reviewed (Pfeffer
and Braunwald 1990; Jugdutt 1993, 1995, 1996, 2003b). A
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Figure 4 Chemical structures of valsartan and some other AT1 receptor blockers.
Abbreviations: AT1, angiotensin II type 1.
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continuum, from post-MI LV remodeling to heart failure
and death as well as other cycles leading to disability and
death in survivors of MI, has been emphasized (Figure 5).
The discovery that LV remodeling post MI, with progressive
LV dilation was a major determinant of morbidity and
mortality, and that this process could be limited by RAAS
inhibition, has led to a major paradigm shift in CV medicine
and has had a tremendous positive impact on post-MI
survival and outcome.
Recent advances in knowledge of the biology of post-
MI remodeling underscore its complexity and the
participation of various molecules including cytokines,
growth factors, and hormones as well as cellular responses
and signaling pathways (Jugdutt 2003a, 2003b). Newer
therapies attempt to modify and modulate these processes
in efforts to optimize outcome. Irrespective of the therapeutic
approach that is selected, outcome depends critically on the
timing and duration of therapy, and attention to the
pathological processes (Jugdutt 1993, 2003b). A caveat with
early unloading therapy after MI emphasizes the avoidance
of hypotension, the paradoxical J-curve effect and
hypoperfusion (Jugdutt 1983, 1991; Swedberg et al 1992).
Thus, low-dose intravenous nitroglycerin for 48 hours given
to high-risk acute MI patients while avoiding hypotension
resulted in anti-remodeling effects and a survival benefit in
anterior MI (Jugdutt and Warnica 1988, 1989).
At least two mechanisms explain the inhibition of LV
structural remodeling in MI survivors by ACE inhibition
and ARBs: (i) a hemodynamic mechanism involving
decreased BP, preload and afterload, and wall stress; and
(ii) a cellular mechanism involving inhibition of Ang II-
induced growth, hypertrophy, and apoptosis (Dzau 1993;
Leri et al 2000).
The rationale for RAAS inhibition using ACE inhibitors
in chronic MI was first provided by experimental studies
showing that chronic captopril therapy reduced LV
dysfunction, LV remodeling and mortality in rats (Pfeffer
et al 1985). Subsequent multicenter RCTs involving over
100 000 patients established that ACE inhibitors improved
survival in patients with acute (ACE 1998) and chronic
(Flather et al 2000) MI. The greatest benefits were found in
high-risk patients with LV dysfunction (Pfeffer 1998). Three
trials, namely the Survival and Ventricular Enlargement
(SAVE) (Pfeffer et al 1992), Acute Infarction Ramipril
Efficacy (AIRE) (1993) and Trandolapril Cardiac Evaluation
(TRACE) (Kober et al 1995), provided strong evidence for
the reduction of mortality and morbidity in MI survivors,
the odds ratio reduction being 0.74% (95% confidence
interval [CI], 0.66%–0.83%) for all-cause mortality, 0.73%
(95% CI, 0.63%–0.85%) for heart failure hospitalization
and 0.80% (95% CI, 0.69%–0.94%) for recurrent MI.
The prevention of progressive LV remodeling, dilation,
and LV dysfunction after MI with ACE inhibitors was
established in the SAVE and Healing and Early Afterload
Reducing Therapy (HEART) trials (St John Sutton et al
1994; Pfeffer et al 1997; Aikawa et al 2001). This anti-
remodeling effect was associated with limitation of heart
failure and improved survival in SAVE (Pfeffer et al 1992).
In the Randomized Evaluation of Strategies for LV
Dysfunction (RESOLVD) trial, the combination of
candesartan and enalapril more effectively prevented LV
remodeling than either alone (McKelvie et al 1999). In the
Veterans Administration Cooperative Vasodilator-Heart
Failure Trial (V-HeFT), increase in LV ejection fraction and
decreased volumes were suggested as markers of regression
of adverse LV remodeling induced by ACE inhibition (Wong
et al 1993). In Val-HeFT, valsartan limited adverse LV
remodeling in heart failure and patients with the most LV
dilation (LV internal dimension in diastole ≥7.5 cm) and
worse ejection fraction (EF < 22%) gained most from its anti-
remodeling effect (Cohn et al, 2001; Wong et al 2004). In
VALIANT, valsartan limited adverse LV remodeling and
improved LV function after MI to a similar degree as
captopril and the combination of valsartan and captopril
(Solomon et al 2005). Importantly, the anti-remodeling effect
of valsartan in both Val-HeFT and VALIANT was associated
with survival benefits (Cohn et al 2001; Pfeffer, McMurray,
et al 2003).
Valsartan and outcome post MI:
VALIANT
The VALIANT trial was designed to assess the superiority
of valsartan over captopril as comparator on top of
conventional therapy, and compared the efficacy and safety
of long-term treatment with valsartan, captopril, and their
combination in high-risk patients with MI and LV systolic
dysfunction and/or heart failure (Pfeffer, McMurray, et al
2003). The study enrolled 14 703 patients, similar to those
in SAVE, AIRE, and TRACE, randomized them at 0.5 to 10
days after acute MI, and followed them for a median of
24.7 months. The patients received valsartan 160 mg BID
(n = 4909), captopril 50 mg TID (n = 4909) or valsartan
50 mg BID plus captopril 50 mg TID (n = 4885). There was
no difference in the primary end-point of all-cause mortality
in the 3 treatment groups. Comparing valsartan withVascular Health and Risk Management 2006:2(2) 132
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captopril, the upper limit of one-sided 97.5% CI was within
the pre-specified margin for non-inferiority for mortality
(p=0.004) and the composite end-point of fatal and non-
fatal events (p<0.001). However, adverse events were most
frequent with the combination of valsartan plus captopril.
Valsartan monotherapy was associated with more
hypotension and renal dysfunction. Captopril monotherapy
was associated with cough, rash, and taste disturbance. The
authors statistically compared the VALIANT results with
previous results of SAVE, AIRE, and TRACE trials using
an imputed placebo, and found that the 25% risk reduction
in all-cause mortality in VALIANT was comparable with
those in the ACE-inhibitor trials (Pfeffer, McMurray, et al
2003). This established conclusively that valsartan is as
effective as an ACE inhibitor in reducing mortality in high-
risk post-MI survivors.
Expanding the story: RAAS
inhibition in heart failure
Heart failure is the end-point of several chronic CV diseases
and is a growing medical and economic burden (O’Connell
2000). Adverse LV remodeling post-MI leads to heart
failure. In heart failure RCTs, >50% of patients were
survivors of MI (Table 3).
Valsartan in heart failure: Val-
HeFT
In Val-HeFT, 5010 patients with systolic heart failure were
randomized to valsartan 160 mg or placebo BID on top of
standard therapy consisting of different ACE inhibitors in
93%, digoxin in 67%, different beta-blockers in 35%, and
the aldosterone blocker spironolactone in 5% (Cohn et al
2001). The patients were followed for an average of 23
months. There was no difference in the primary end-point
of all-cause mortality. However, valsartan reduced the
composite end-point of mortality and morbidity by 13.2%
(relative rate of 0.87; 97.5% CI, 0.77–0.97; p = 0.009).
Valsartan also improved clinical signs and symptoms of heart
failure (p<0.01). Heart failure hospitalizations decreased by
24% with valsartan. Post-hoc analysis of the combined end-
point revealed that valsartan had a favorable effect in patients
receiving neither ACE inhibitors nor beta-blockers, but an
adverse effect in the 30% of patients receiving the
combination of valsartan, ACE inhibitor, and beta-blocker
(Cohn et al 2001). Since only 5% of the patients were on
spironolactone, this combination was not analyzed. Overall,
the target dose of valsartan was well tolerated and valsartan
was most beneficial in patients not taking ACE inhibitors.
There are several other noteworthy features of Val-HeFT.
First, patients already taking ARBs were excluded. Second,
valsartan produced sustained reduction of aldosterone in
all subgroups, despite different clinical outcomes (Cohn et
al 2003). Third, the V-HeFT group (Baruch et al 1999)
previously demonstrated physiologically active levels of
Ang II in chronic heart failure patients receiving standard
long-term ACE inhibitor therapy while 4 weeks of valsartan
decreased plasma aldosterone and norepinephrine. Although
Ang II levels while taking valsartan without ACE inhibitors
were not measured, Ang II did not rise with co-
administration of valsartan and an ACE inhibitor.
Tolerability and safety of valsartan
post-MI and in heart failure
Overall, ARBs including valsartan are well tolerated.
Tolerability in Optimal Therapy in MI with the Ang II
Antagonist Losartan (OPTIMAAL) (Dickstein et al 2002)
and Evaluation of Losartan in the Elderly (ELITE) (Pitt et
al 1997) favored losartan over captopril after MI and in heart
failure, respectively. Tolerability to candesartan in heart
failure patients intolerant to ACE inhibitors was
demonstrated in the Candesartan in Heart Failure:
Assessment of Reduction in Mortality and Morbidity
(CHARM) trial (Granger et al 2003; McMurray et al 2003;
Pfeffer, Swedberg, et al 2003; Yusuf et al 2003). The
CHARM data provides a useful guide since the patients who
developed cough with the ACE inhibitor had a 0.3% chance
Table 3 Cause of heart failure in some trials of ACE inhibitors
and ARBs
Year Trial Cause of heart failure (history)
1987 CONSENSUS 72%–74% CAD; 47%–48% MI
1991 SOLVD, symptomatic 70%–72% ischemia; 65%–66% MI
1992 SOLVD, asymptomatic 83%–84% ischemia; 79%–81% MI
1997 ELITE 34%–35% ischemia; 25% MI
1999 RALES 55% ischemia
2000 ELITE II 79% ischemia; 58%–59% MI
2001 Val-HeFT 57%–58% CAD
2003 CHARM-Overall 52%–53% MI
2003 CHARM–Added 62%–63% ischemia; 55%–56% MI
2003 CHARM-Alternative 67%–70% ischemia; 61%–62% MI
2003 CHARM-Preserved 56% ischemia; 44%–45% MI
Abbreviations: CAD, coronary artery disease; CHARM, Candesartan in Heart
Failure: Assessment of Reduction in Mortality and Morbidity; CONSENSUS,
Cooperative New Scandinavian Enalapril Survival Study; ELITE, Evaluation of
Losartan in the Elderly; MI, myocardial infarction, RALES, Randomized Aldactone
Evaluation Study; SOLVD, Studies of Left Ventricular Dysfunction, Val-HeFT,
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of developing it with candesartan, while patients who
developed angioedema, hypotension, and renal impairment
with the ACE inhibitor had a 2.6%, 9.1%, 23.1% probability,
respectively, of developing them with candesartan.
Tolerability of valsartan in heart failure was confirmed
in Val-HeFT (Cohn et al 2001). Thus, the adverse event
rate for valsartan was similar to placebo although serum
creatinine increased slightly with valsartan. The finding of
a potentially adverse effect of the combination of valsartan
with an ACE inhibitor and a beta-blocker (triple therapy)
suggests the need for caution with combination therapy.
However, this finding should not detract from the other
important benefits in Val-HeFT. Thus, in patients not taking
ACE inhibitors, valsartan decreased mortality by 33%
(p = 0.017) and the combined mortality and morbidity end-
point by 44% (p < 0.001) (Maggioni et al 2002; Carson et al
2003). The overall findings of Val-HeFT support the use of
valsartan as an alternative in heart failure patients intolerant
to ACE inhibitors, but not as an add-on to ACE inhibitor
therapy. Valsartan also improved other secondary end-
points, reducing the incidence of atrial fibrillation by 37%
(Maggioni et al 2005), improving LV internal diastolic
diameter and ejection fraction in all groups except in those
taking valsartan with an ACE inhibitor and a beta-blocker
(Wong et al 2004), and reducing brain natriuretic peptide
(BNP) and plasma norepinephrine (Latini et al 2002).
In the post-MI patients in VALIANT (Pfeffer, McMurray,
et al 2003), the finding that valsartan on top of captopril
increased adverse events without improving survival or the
secondary outcomes, despite more BP lowering and
increased rate of intolerance, did not support the concept of
incremental benefits with combination therapy. More
patients were not taking the study drug at one year in the
valsartan plus captopril than in captopril (19.0 vs 16.8%,
p = 0.007) or valsartan (15.3%) groups. Hypotension was
common, and more frequent (p<0.05) with the combination
(18.2%) than with valsartan (15.1%) or captopril (11.9%)
monotherapy, underscoring the need for BP monitoring after
acute MI. Cough and rash were more common with captopril
and renal impairment with valsartan (4.9%) or valsartan plus
captopril (4.8%).
A recent editorial cautioned against ARBs increasing MI
(Verma and Strauss 2004), based on data from the Valsartan
Antihypertensive Long-term Use Evaluation Trial (VALUE)
(19% increase) and CHARM (36% increase) compared with
ACE inhibitors (>20% decrease). However, a post-hoc
analysis of VALIANT showed a downward trend in the
numbers of patients developing recurrent MI: 840 for
captopril, 820 for valsartan and 775 for the combination
(McMurray 2005). Furthermore, a meta-analysis of RCTs
using ARBs showed that ARBs were not associated with an
excess risk of MI and the frequency of MI was similar for
ARBs versus placebo or ACE inhibitors (Verdecchia et al
2005).
A meta-analysis of ARBs in chronic heart failure and
high-risk acute MI patients showed that ARBs similarly
reduced all-cause mortality and heart failure deaths as ACE
inhibitors and should be considered as suitable alternatives
to ACE inhibitors (Lee et al 2004). The authors found that
ARBs produced a statistically significant reduction in all-
cause mortality relative to placebo, contrary to a previous
meta-analysis (Jong et al 2002).
Expanding the RAAS-inhibition
paradigm in post-MI survivors
Six points are pertinent. First, over the last decade, two RCTs
have investigated the benefits of using aldosterone
antagonists in patients with heart failure and MI. The
rationale was that Ang II stimulates the release of aldosterone
(Figures 1, 2) thereby activating the mineralocorticoid
receptor and activation of this receptor persists despite the
use of ACE inhibitors, ARBs and beta-blockers. Aldosterone
blockade was shown to limit LV remodeling, fibrosis, matrix
metalloproteinase (MMP) activation and angiogenesis in the
coronary embolization model of heart failure in dogs (Suzuki
et al 2002), and limit collagen synthesis and LV remodelling
in post-MI patients (Modena et al 2001). In the Randomized
Aldactone Evaluation Study (RALES) (Pitt et al 1999), 1663
patients with chronic heart failure (LV ejection fraction
≤35%) received the aldosterone blocker spironolactone or
placebo on top of background therapy with an ACE inhibitor,
diuretic, digoxin, and beta-blocker. RALES was prematurely
terminated due to the early finding of a 30% reduction in
all-cause mortality (p < 0.001). In the Eplerenone Post-Acute
Myocardial Infarction Heart Failure Efficacy and Survival
Study (EPHESUS) (Pitt et al 2003), 6642 patients with acute
MI, LV ejection fraction ≤40%, and heart failure were
randomized to receive the selective aldosterone blocker,
eplerenone or placebo on top of optimal background therapy.
Eplerenone reduced all-cause mortality by 15% (p = 0.008)
and cardiovascular mortality by 17% (p = 0.005). In a
substudy of RALES (Zannad et al 2000), spironolactone
was associated with increased levels of markers of collagen
synthesis, suggesting that limitation of excessive
extracellular matrix (ECM) turnover may have contributedVascular Health and Risk Management 2006:2(2) 134
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to the benefits. In a substudy of EPHESUS (Pitt et al 2005),
eplerenone was shown to reduce the 30-day all-cause
mortality after acute MI, supporting early initiation of
therapy.
Second, polypharmacy is becoming common in post-
MI survivors and heart failure. Although experimental
studies suggest that combination therapy is more beneficial
than monotherapy, this can result in unsuspected interactions
among known effects as well as previously not so well
known pleotropic effects. Although one potential concern
with use of ACE-inhibitors, ARBs, and aldosterone
antagonists in combination is that each drug can effectively
decrease infarct collagen as well non-infarct interstitial
fibrosis (Jugdutt 2003b), the evidence of benefits in the
RCTs and demonstrated anti-remodeling collectively serve
to allay this concern somewhat. While the effect may
improve LV diastolic function, the possibility remains that
reduction in collagen matrix may increase LV distensibility
on the long-term and contribute to deterioration, especially
in patients with large transmural MI. This area needs further
study.
Another concern unmasked by Val-HeFT was a possible
interaction of ARBs with beta-blockers. In addition, both
VALIANT and Val-HeFT drew attention to potential adverse
effects with the combination of ARBs and ACE inhibitors.
Third, although most patients with acute MI receive
reperfusion therapy that may be associated with significant
reperfusion injury and stunning (Solomon et al 2001), there
is little data on whether ARBs might improve functional
recovery after reperfused MI. Recently in the dog model of
reperfusion after prolonged ischemia, valsartan was shown
to improve LV function, limit acute infarct remodeling and
infarct size, and normalize the balance between MMP-9 and
the tissue inhibitor of MMP (TIMP-3), suggesting improved
ECM remodeling (Sawicki et al 2004). In the same model,
valsartan reversed the changes in metabolic, functional and
structural proteins induced by post-ischemic reperfusion
(Jugdutt and Sawicki 2004; Sawicki and Jugdutt 2004). In
both dog and rat models of post-ischemic reperfusion,
valsartan induced cardioprotection, which was associated
with enhanced AT2 receptor expression (Jugdutt and Menon
2004a, 2004b). Collectively, the findings suggest that
valsartan limits myocardial reperfusion injury after
reperfused MI and this effect may involve improved ECM
remodeling and AT2 stimulation.
Fourth, experimental evidence suggests that the
combination of valsartan and enalapril produces added
benefits relative to monotherapy with respect to endothelial
function (de Gasparo et al 2002) and combination therapy
is currently being evaluated in patients with vascular disease
(Yusuf 2002). Although AT2 receptor stimulation may
explain the vasculoprotective effects of ARBs and ACE
inhibitors, recent experimental evidence suggests that AT2
receptor stimulation may promote cardiac hypertrophy and
vascular fibrosis, and reduce neovascularization in ischemic
tissue (Levy 2004). These negative effects of AT2 stimulation
may explain why ARBs are clinically not found to be
superior to ACE inhibitors with respect to some end-points.
Fifth, should ARBs such as valsartan be considered for
all survivors of MI? Can ARBs prevent both infarct and
non-infarct related complications in MI survivors? The
evidence from VALIANT and Val-HeFT supports the use
of valsartan as an alternative to ACE inhibitors in high-risk
patients with LV systolic dysfunction and/or heart failure
as well as in chronic heart failure, including that after MI.
In view of the evidence gap, it might be prudent not to
extrapolate the existing data and extend the use to include
all post-MI patients.
Sixth, several RCTs in hypertension have shown that
RAAS inhibition reverses adverse cardiac remodeling and
improves prognosis beyond BP control, and valsartan
showed similar efficacy relative to ACE inhibitors in that
respect (Corea et al 1996; Langtry and McClellen 1999).
Collectively, the RCTs in hypertension suggest that, besides
BP control and CV protection, reduction of stroke and new-
onset diabetes are important long-term benefits with ACE-
inhibitors and ARBs. Results of RCTs and substudies in
heart failure and MI favor these agents, including valsartan,
for prevention of adverse atrial remodeling, atrial fibrillation
and stroke, and recent onset diabetes in MI survivors.
With respect to stroke, cumulative evidence indicates
that atrial fibrillation leads to embolism and stroke and is
associated with adverse outcome in MI and heart failure,
and RAAS inhibition can decrease the incidence of atrial
fibrillation. In a substudy of VALIANT (Velazquez et al
2004), heart failure and/or LV systolic dysfunction preceded
80.3% of all in-hospital deaths, and that group had higher
rates of atrial fibrillation (16%) and stroke (2.2%). In another
substudy (Szummer et al 2005), in-hospital stroke was found
in 1.5% of the post-MI heart failure patients, in-hospital
mortality was greater in patients with stroke (27.2 vs 6.5%,
p<0.001), heart failure on admission increased the risk of
stroke, and atrial fibrillation was more frequent in stroke
victims. In a substudy of Val-HeFT, atrial fibrillation was
associated with worse outcome in chronic heart failure
patients and the addition of valsartan reduced atrialVascular Health and Risk Management 2006:2(2) 135
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fibrillation by 37% (Maggioni et al 2005), indicating that
chronic therapy with valsartan on top of ACE inhibitors and
beta-blockers reduces atrial fibrillation.
With respect to diabetes, VALUE (Julius et al 2004)
noted a decrease in new-onset diabetes with valsartan in
hypertensive patients. A substudy of VALIANT confirmed
that diabetes, whether new-onset or known, predicts poor
long-term outcomes in high-risk MI patients (Aguilar et al
2004). In CHARM (Pfeffer, Swedberg, et al 2003),
candesartan was suggested to ‘prevent’ diabetes. This effect
of ARBs may have contributed to CV protection in RCTs.
Conclusions and future directions
The totality of the evidence from RCTs to date supports the
use of ACE inhibitors as first line therapy in post MI
survivors and ARBs as proven life saving alternatives. For
patients intolerant to ACE inhibitors, valsartan is a prime
candidate. Valsartan is approved for the treatment of heart
failure and hypertension, as is candesartan. Potential
additional indications for ARBs include: (i) limiting
ventricular and atrial remodeling in MI survivors; (ii)
preventing atrial fibrillation and stroke, especially in MI
survivors; (iii) improving BP control, cardioprotection,
vasculoprotection, and CV outcomes in hypertensive
patients with LV hypertrophy; (iv) reducing new-onset
diabetes and insulin resistance; (v) preventing progression
of atherosclerosis and its complications. Aggressive
measures, including the use of RAAS inhibition with ARBs
and/or ACE inhibitors and aldosterone antagonists on top
of approved background therapies, are needed in MI
survivors for closing the healthcare gap and reducing risk
in high-risk CV patients who do not achieve treatment targets
recommended by evidence-based guidelines.
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